Conversations with Children’s Cancer Cause
In the fall of 2021, we launched a new virtual series aimed at elevating voices from the childhood cancer community.
ON THE 118TH CONGRESS AND COMPREHENSIVE CANCER SURVIVORSHIP ACT:
Conversation with Sue Emmer of Emmer Consulting
January 2023
Our first Conversation of 2023 features Sue Emmer, Policy Counsel to Children's Cancer Cause, about what to expect from the 118th Congress and some of our top legislative priorities, including the Comprehensive Cancer Survivorship Act, the Childhood Cancer STAR Act, the Accelerating Kids’ Access to Care Act, and the Gabriella Miller Kids First Research Act 2.0
ON THE CARDIAC LATE EFFECTS EL-PFDD MEETING:
Conversation with Greg Aune, MD, PhD
October 2022
Our October Conversation features Dr. Greg Aune, a pediatric oncologist and pediatric cancer survivor. Dr. Aune discusses some of the top takeaways from our recent externally-led Patient Focused Drug Development meeting on the topic of Reducing Cardiac Late Effects in Childhood Cancer Survivors, including the importance of giving families a platform to share their powerful stories.
ON CHILDHOOD CANCER SURVIVORSHIP AND CHEMO-INDUCED HEARING LOSS:
Conversation with Dr. Emily Tonorezos
April 2022
Our April Conversation features Emily S. Tonorezos, MD, MPH, director of the Office of Cancer Survivorship, part of the Division of Cancer Control and Population Sciences at the National Cancer Institute (NCI). We discuss what NCI is focused on right now in childhood cancer survivorship and new developments in the field of chemotherapy-induced hearing loss (the subject of our 2018 Patient-Focused Drug Development meeting).
ON TRANSITIONS IN CARE:
Conversation with Dr. Monica Gramatges
January 2022
Our January Conversation features Dr. Monica Gramatges, Associate Section Chief of Oncology and Research Co-Director of the Long-Term Survivor Program at Texas Children’s. We discuss the types of transitions in care faced by childhood cancer families along the spectrum of treatment and survivorship.
ON CLINICAL RESEARCH ORGANIZATIONS:
Conversation with Missy Hansen, MSN, APRN, CPNP, CPHON
December 2021
Our December Conversation features Missy Hansen, Pediatric Strategy Liaison at the Center for Pediatric Clinical Development at ICON. We discuss the role of Clinical Research Organizations and how collaboration is key in developing new therapies for children and ensuring global access.
“Our children are actually uniquely vulnerable to shortages. In the last 5 years, 75% of the 20 most essential pediatric cancer drugs have been in shortage. ”
ON DRUG SHORTAGES:
Conversation with Laura Bray, MBA November 2021
Our November Conversation features Laura Bray, MBA, Chief Change Maker with Angels for Change. We dive into the critical topic of drug shortages, an issue that personally impacted Laura's family when her daughter Abby was in need of a life-saving drug that was part of a prolonged global shortage.
ON SURVIVORSHIP:
Conversation with Smita Bhatia, MD, PhD
October 2021
Julie Taylor, our Director of Programs and Operations, discusses survivorship with Dr. Smita Bhatia of The University of Alabama at Birmingham. In this Conversation, Dr. Bhatia talks about long-term follow-up care, transitioning from pediatric to adult care, access to care for under-served populations, and more.
ON TWO DECADES OF PROGRESS:
Conversation with Susan L. Weiner, PhD, September 2021
Children’s Cancer Cause CEO Steve Wosahla asks Susan to speak on some of the milestone moments over the past two decades that have led to improved research, treatment, and care for children with cancer. Susan discusses her motivation for founding the Children’s Cancer Cause in 1999 and tells us about some of the major events since that jump-started significant progress in pediatric oncology, including the drafting of the human genome and the formation of the Children’s Oncology Group.
